A Randomized, Open-Label, Phase III Trial of Afatinib (A) Vs Erlotinib (E) As Second-Line Treatment of Patients (Pts) with Advanced Squamous Cell Carcinoma (Scc) of the Lung Following First-Line Platinum-Based Chemotherapy: Lux-Lung 8 (Ll8)

Second Line ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase

LUX-Lung 8: A Global Phase III Trial of Afatinib (A) vs Erlotinib (E) as Second-Line Treatment in Patients (Pts) With Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy

CHEST Journal ◽

10.1378/chest.2272584 ◽

2015 ◽

Vol 148 (4) ◽

pp. 585A

Author(s):

Vera Hirsh ◽

Shirish Gadgeel ◽

Jean-Charles Soria ◽

Enriqueta Felip ◽

Manuel Cobo ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Phase Iii Trial ◽

Platinum Based Chemotherapy

Lux-Lung 8: A Randomized, Open-Label, Phase III Trial of Afatinib vs. Erlotinib in Patients with Advanced Squamous Cell Carcinoma of the Lung as Second-Line Therapy Following First-Line Platinum-Based Chemotherapy

Annals of Oncology ◽

10.1016/s0923-7534(20)33072-6 ◽

2012 ◽

Vol 23 ◽

pp. ix174 ◽

Cited By ~ 2

Author(s):

G. Goss ◽

S. Lu ◽

E. Felip ◽

A. Ardizzoni ◽

V. Georgoulias ◽

...

Keyword(s):

Phase Iii ◽

Second Line ◽

First Line ◽

Open Label ◽

Second Line Therapy ◽

Phase Iii Trial ◽

Line Therapy ◽

Open Label Phase

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy

Clinical Lung Cancer ◽

10.1016/j.cllc.2017.06.002 ◽

2018 ◽

Vol 19 (1) ◽

pp. 74-83.e11 ◽

Cited By ~ 9

Author(s):

Enriqueta Felip ◽

Vera Hirsh ◽

Sanjay Popat ◽

Manuel Cobo ◽

Andrea Fülöp ◽

...

Keyword(s):

Phase Iii ◽

Second Line ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

Life Improvement

Afatinib (A) Vs Erlotinib (E) as Second-Line Treatment of Patients (PTS) with Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy: Lux-Lung 8 (LL8), a Phase Iii Global Trial

Annals of Oncology ◽

10.1093/annonc/mdv050.12 ◽

2015 ◽

Vol 26 ◽

pp. i29 ◽

Cited By ~ 3

Author(s):

G.D. Goss ◽

E. Felip ◽

M. Cobo ◽

S. Lu ◽

V. Georgoulias ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Platinum Based Chemotherapy

Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8100 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8100-8100

Author(s):

Shirish M. Gadgeel ◽

Manuel Cobo Dols ◽

Enriqueta Felip ◽

Jean-Charles Soria ◽

Ki Hyeong Lee ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Patient Reported Outcome ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Patient Reported

Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, phase 3 LUX-Lung 8 (LL8) trial of afatinib (A) versus erlotinib (E) for the second-line treatment of advanced squamous cell carcinoma (SCC) of the lung.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e20510 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e20510-e20510 ◽

Cited By ~ 1

Author(s):

Glenwood D. Goss ◽

Ki Hyeong Lee ◽

Enriqueta Felip ◽

Manuel Cobo ◽

Konstantinos N. Syrigos ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Line Treatment ◽

Second Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial

10.1183/13993003.congress-2015.oa265 ◽

2015 ◽

Author(s):

Shirish Gadgeel ◽

Jean-Charles Soria ◽

Enriqueta Felip ◽

Manuel Cobo ◽

Shun Lu ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Phase Iii Trial

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2020.06.011 ◽

2020 ◽

Vol 15 (10) ◽

pp. 1647-1656 ◽

Cited By ~ 4

Author(s):

Solange Peters ◽

Sarah Danson ◽

Baktiar Hasan ◽

Urania Dafni ◽

Niels Reinmuth ◽

...

Keyword(s):

Advanced Nsclc ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

European Organisation ◽

Open Label Phase ◽

First Line Treatment

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

Annals of Oncology ◽

10.1093/annonc/mdz388 ◽

2019 ◽

Vol 30 (11) ◽

pp. 1831-1839 ◽

Cited By ~ 2

Author(s):

Y. Guo ◽

M.-J. Ahn ◽

A. Chan ◽

C.-H. Wang ◽

J.-H. Kang ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Open Label ◽

Phase Iii Trial ◽

Asian Patients ◽

Metastatic Squamous Cell Carcinoma ◽

Head Neck

Randomized, Open-Label, Phase III Trial Of Pazopanib Versus Sunitinib In First-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma (MRCC): Results of the Comparz Trial

Annals of Oncology ◽

10.1016/s0923-7534(20)34325-8 ◽

2012 ◽

Vol 23 ◽

pp. ixe13 ◽

Cited By ~ 26

Author(s):

R. Motzer ◽

T.E. Hutson ◽

J. Reeves ◽

R. Hawkins ◽

J. Guo ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

First Line Treatment